Your browser is no longer supported. Please, upgrade your browser.
Settings
ABUS Arbutus Biopharma Corporation daily Stock Chart
ABUS [NASD]
Arbutus Biopharma Corporation
Index- P/E- EPS (ttm)-1.79 Insider Own40.87% Shs Outstand57.23M Perf Week66.29%
Market Cap85.27M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float35.31M Perf Month62.70%
Income-100.00M PEG- EPS next Q-0.27 Inst Own37.10% Short Float3.96% Perf Quarter-8.59%
Sales4.60M P/S18.54 EPS this Y35.00% Inst Trans-0.63% Short Ratio3.01 Perf Half Y-37.66%
Book/sh0.58 P/B2.57 EPS next Y-8.40% ROA-45.70% Target Price9.32 Perf Year-71.18%
Cash/sh1.67 P/C0.89 EPS next 5Y- ROE-159.30% 52W Range0.82 - 5.66 Perf YTD-61.10%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-105.50% 52W High-74.82% Beta1.74
Dividend %- Quick Ratio11.30 Sales past 5Y-17.40% Gross Margin- 52W Low73.48% ATR0.14
Employees80 Current Ratio11.30 Sales Q/Q-41.70% Oper. Margin- RSI (14)63.00 Volatility23.32% 11.80%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume2.71 Prev Close1.49
ShortableYes LT Debt/Eq0.00 EarningsNov 06 BMO Payout- Avg Volume464.39K Price1.42
Recom1.90 SMA2040.24% SMA509.88% SMA200-40.56% Volume204,151 Change-4.36%
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Oct-04-19Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Dec-13-16Downgrade Chardan Capital Markets Buy → Neutral $4 → $3
Nov-30-16Upgrade Chardan Capital Markets Neutral → Buy $4
Oct-14-16Upgrade Chardan Capital Markets Sell → Neutral $3
Aug-05-16Downgrade Leerink Partners Outperform → Mkt Perform
Jul-08-16Downgrade Chardan Capital Markets Neutral → Sell $3.25 → $2.75
Jun-16-16Upgrade Chardan Capital Markets Sell → Neutral $3.25
May-16-16Initiated Chardan Capital Markets Sell $3.25
Nov-06-15Reiterated RBC Capital Mkts Outperform $35 → $20
Sep-02-15Initiated JMP Securities Mkt Outperform
Nov-06-19 09:35AM  Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM  Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 07:13AM  We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-30-19 10:33AM  Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
07:30AM  Arbutus to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-10-19 02:59PM  Bucks biopharm firm halts study of potential hepatitis B cure American City Business Journals
Oct-04-19 07:32AM  The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga -28.67%
Oct-03-19 04:05PM  Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B GlobeNewswire
Sep-26-19 07:30AM  Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire -6.25%
Sep-19-19 06:17AM  Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop? Simply Wall St.
Aug-20-19 04:05PM  Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors GlobeNewswire
Aug-06-19 07:30AM  Arbutus to Participate at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 08:55AM  Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM  Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-19 07:30AM  Arbutus to Report Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 10:34AM  Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-15-19 04:05PM  Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B GlobeNewswire
Jul-04-19 04:09PM  Heres What Hedge Funds Think About Arbutus Biopharma Corp (ABUS) Insider Monkey
Jul-03-19 07:31AM  The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief Benzinga -5.26%
Jul-02-19 04:01PM  Arbutus Sells Part of its ONPATTRO (patisiran) Royalty Interest to OMERS GlobeNewswire
Jun-21-19 09:20AM  Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up Zacks -6.78%
Jun-20-19 07:30AM  Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729 GlobeNewswire +37.21%
Jun-17-19 07:30AM  Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. GlobeNewswire +24.66%
Jun-13-19 08:30AM  Arbutus to Participate at JMP Securities Life Sciences Conference GlobeNewswire
May-22-19 12:56PM  Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO? Simply Wall St. -10.30%
May-13-19 08:30AM  Arbutus to Present at Upcoming May 2019 Conferences GlobeNewswire -6.38%
May-06-19 05:15PM  Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:45PM  Arbutus: 1Q Earnings Snapshot Associated Press
04:01PM  Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-29-19 08:30AM  Arbutus to Report First Quarter 2019 Financial Results GlobeNewswire
Apr-25-19 10:33AM  Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -5.84%
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-08-19 08:37AM  Top Ranked Momentum Stocks to Buy for April 8th Zacks
Apr-04-19 03:03PM  Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last? Simply Wall St. +6.22%
Mar-07-19 10:26PM  Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives GlobeNewswire
Feb-28-19 08:30AM  Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update GlobeNewswire
Feb-04-19 07:35AM  Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-19 10:13AM  Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register? Simply Wall St.
Dec-23-18 03:40AM  Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)? Insider Monkey
Dec-11-18 07:55AM  New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-08-18 10:03PM  Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy? Insider Monkey
Dec-05-18 11:20AM  Why Arbutus Biopharma Corporations (NASDAQ:ABUS) CEO Pay Matters To You Simply Wall St.
Nov-26-18 04:41PM  Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors GlobeNewswire -5.60%
Nov-21-18 08:41AM  Options Traders Expect Huge Moves in Arbutus (ABUS) Stock Zacks +5.17%
Nov-07-18 04:01PM  Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-18 08:30AM  Arbutus to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-22-18 08:30AM  Arbutus Names New Members to its Board of Directors GlobeNewswire
Oct-19-18 08:25AM  New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-17-18 02:25PM  What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)? Simply Wall St.
Oct-10-18 10:23AM  Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks -23.83%
08:00AM  Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics ACCESSWIRE
Oct-09-18 03:23PM  Here's Why Arbutus Biopharma Corp. Is Tanking Today Motley Fool -33.99%
08:30AM  Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer GlobeNewswire
Oct-02-18 08:30AM  Arbutus to Present at Chardans Genetic Medicines Conference GlobeNewswire
Sep-24-18 09:00AM  Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock? Zacks
Aug-28-18 08:30AM  Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference GlobeNewswire
Aug-21-18 07:35AM  Consolidated Research: 2018 Summary Expectations for GSV Capital, NantHealth, Gold Fields, Sogou Inc. Sponsored ADR, Clementia Pharmaceuticals, and Arbutus Biopharma Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-13-18 08:30AM  Arbutus LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis GlobeNewswire
Aug-09-18 08:30AM  Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 04:00PM  Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Arbutus Biopharma Corporation to Host Earnings Call ACCESSWIRE
Jul-20-18 09:31AM  Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue? Zacks
Jul-19-18 10:26AM  Harry Boxers three drug stocks to watch MarketWatch
08:30AM  Arbutus to Report Second Quarter 2018 Financial Results GlobeNewswire
Jul-14-18 02:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch +8.49%
Jul-10-18 07:00AM  Arbutus Presents Corporate Update on Key Milestones GlobeNewswire
Jul-07-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-06-18 10:59AM  Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run Benzinga
09:02AM  Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6% Zacks
Jun-18-18 08:30AM  Arbutus Biopharma to Present at First Annual Roivant Pipeline Day GlobeNewswire +6.30%
Jun-07-18 05:44PM  Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer GlobeNewswire
Jun-06-18 07:40AM  Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-07-18 07:10AM  Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib ACCESSWIRE
May-03-18 05:28PM  Arbutus: 1Q Earnings Snapshot Associated Press
04:15PM  Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer Forbes
04:00PM  Arbutus Announces Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
Apr-30-18 09:00AM  Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
Apr-12-18 12:00PM  Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018 GlobeNewswire
Apr-11-18 05:24PM  Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases GlobeNewswire
08:20AM  New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-28-18 05:54PM  Arbutus to Present HBV Data at 2018 EASL Liver Meeting GlobeNewswire
Mar-22-18 03:51AM  Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT Thomson Reuters StreetEvents +7.95%
03:51AM  Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-18 12:57PM  Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines Benzinga -5.71%
Mar-16-18 08:20AM  Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-15-18 11:16AM  Edited Transcript of ABUS earnings conference call or presentation 14-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -7.08%
Mar-14-18 04:00PM  Arbutus Announces Corporate Update and Year-End 2017 Financial Results GlobeNewswire -5.83%
10:22AM  Arbutus Biopharma Corporation (NASDAQ:ABUS) Is Expected To Breakeven Simply Wall St.
Mar-12-18 09:00AM  Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results GlobeNewswire
Feb-22-18 04:35PM  Arbutus Settles Litigation, Terminating Acuitas Rights to LNP Technology GlobeNewswire
Feb-14-18 08:50PM  Arbutus Enters Exclusivity Agreement with Roivant Sciences GlobeNewswire
Feb-13-18 09:36PM  Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO GlobeNewswire +6.60%
Feb-08-18 08:30AM  Arbutus Consolidates HBV Business Around Warminster, PA Site GlobeNewswire
Feb-05-18 03:39PM  Should Arbutus Biopharma Corporations (NASDAQ:ABUS) Recent Earnings Decline Worry You? Simply Wall St.
Jan-16-18 08:30AM  Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences GlobeNewswire
Nov-28-17 07:18AM  Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017 Capital Cube -7.81%
Nov-27-17 09:00AM  Arbutus Announces Presentations at HepDART 2017 GlobeNewswire +5.79%
Nov-16-17 01:40PM  Arbutus LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran GlobeNewswire
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murray Mark J.DirectorNov 28Option Exercise1.3525,00033,750341,396Nov 30 04:55 PM